Please assess the completion status of the following clinical trial:

Trial Title: Auto-immunity in Lupus Patients After Influenza Vaccine

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria :~* 18 years of age and older~* informed consent signed~* LES patients who meet the American College of Rheumatology (ACR) diagnostic criteria of SLE~* Patient able to attend all visit schedule during the month following influenza vaccine administration~* Clinical examination performed prior final inclusion with results communicated to the patient~Exclusion criteria :~* For women, being pregnant or positive pregnancy test~* Positive for HCV, HIV and HBV~* Patient treated with rituximab (anti-CD20) or stopped for less than a year.~* Patient for whom a treatment majorization is suspected within the month following influenza vaccine administration.~* Hypersensitivity to active substances, eggs and to one of the vaccine components~* Other vaccinations within the last 30 days before the inclusion at J0~* Administration of blood products such as immunoglobulins within the last 90 days before J0~* Progressive cancer, cirrhoses~* Acute severe illness within the last 30 days before inclusion at J0~* Patient non affiliated to a health social security system~* Planned participation to another clinical study during the present study period~* patient deprived of freedom by an administrative or court order

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vaccine group (Type: EXPERIMENTAL): single group: all included patients will receive the vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).